These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8364193)

  • 1. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase.
    Richards SM; Olson TA; McPherson JM
    Blood; 1993 Sep; 82(5):1402-9. PubMed ID: 8364193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration.
    Rosenberg M; Kingma W; Fitzpatrick MA; Richards SM
    Blood; 1999 Mar; 93(6):2081-8. PubMed ID: 10068682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaucher's disease: lack of antibody response in 12 patients following repeated intravenous infusions of mannose terminal glucocerebrosidase.
    Murray GJ; Howard KD; Richards SM; Barton NW; Brady RO
    J Immunol Methods; 1991 Mar; 137(1):113-20. PubMed ID: 2010615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease.
    Brady RO; Murray GJ; Oliver KL; Leitman SF; Sneller MC; Fleisher TA; Barton NW
    Pediatrics; 1997 Dec; 100(6):E11. PubMed ID: 9382912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies.
    Zhao H; Bailey LA; Grabowski GA
    Blood Cells Mol Dis; 2003; 30(1):90-6. PubMed ID: 12667990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gaucher's disease: lack of antibody response to intravenous glucocerebrosidase.
    Britton DE; Leinikki PO; Barranger JA; Brady RO
    Life Sci; 1978 Dec; 23(25):2517-9. PubMed ID: 732537
    [No Abstract]   [Full Text] [Related]  

  • 8. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.
    Schiffmann R; Heyes MP; Aerts JM; Dambrosia JM; Patterson MC; DeGraba T; Parker CC; Zirzow GC; Oliver K; Tedeschi G; Brady RO; Barton NW
    Ann Neurol; 1997 Oct; 42(4):613-21. PubMed ID: 9382473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase.
    Ponce E; Moskovitz J; Grabowski G
    Blood; 1997 Jul; 90(1):43-8. PubMed ID: 9207436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease.
    Barton NW; Brady RO; Dambrosia JM; Doppelt SH; Hill SC; Holder CA; Mankin HJ; Murray GJ; Zirzow GC; Parker RI
    J Pediatr; 1992 Feb; 120(2 Pt 1):277-80. PubMed ID: 1735829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of polyclonal antibodies against recombinant human glucocerebrosidase produced in Escherichia coli.
    Novo JB; Oliveira ML; Magalhães GS; Morganti L; Raw I; Ho PL
    Mol Biotechnol; 2010 Nov; 46(3):279-86. PubMed ID: 20574770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis of the acid beta-glucosidase gene in a patient with type 3 Gaucher disease and neutralizing antibody to alglucerase.
    Germain DP; Kaneski CR; Brady RO
    Mutat Res; 2001 Nov; 483(1-2):89-94. PubMed ID: 11600137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.
    Grabowski GA; Barton NW; Pastores G; Dambrosia JM; Banerjee TK; McKee MA; Parker C; Schiffmann R; Hill SC; Brady RO
    Ann Intern Med; 1995 Jan; 122(1):33-9. PubMed ID: 7985893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase.
    Rosenthal DI; Doppelt SH; Mankin HJ; Dambrosia JM; Xavier RJ; McKusick KA; Rosen BR; Baker J; Niklason LT; Hill SC
    Pediatrics; 1995 Oct; 96(4 Pt 1):629-37. PubMed ID: 7567322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    Barton NW; Brady RO; Dambrosia JM; Di Bisceglie AM; Doppelt SH; Hill SC; Mankin HJ; Murray GJ; Parker RI; Argoff CE
    N Engl J Med; 1991 May; 324(21):1464-70. PubMed ID: 2023606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of alglucerase infused into Gaucher disease patients to localize in marrow macrophages.
    Beutler E; Kuhl W; Vaughan LM
    Mol Med; 1995 Mar; 1(3):320-4. PubMed ID: 8529110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacokinetic analysis of a novel enzyme replacement therapy with Gene-Activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease.
    Zimran A; Loveday K; Fratazzi C; Elstein D
    Blood Cells Mol Dis; 2007; 39(1):115-8. PubMed ID: 17391996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R; Arndt S; Levin JB
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-reacting material in Gaucher disease fibroblasts.
    Beutler E; Kuhl W; Sorge J
    Proc Natl Acad Sci U S A; 1984 Oct; 81(20):6506-10. PubMed ID: 6593712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
    Pastores GM; Turkia HB; Gonzalez DE; Ida H; Tantawy AA; Qin Y; Qiu Y; Dinh Q; Zimran A
    Blood Cells Mol Dis; 2016 Jul; 59():37-43. PubMed ID: 27282565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.